How Was Time Saved?

**RESEARCH**
The SARS-CoV-2 genetic sequence was identified and tested right away thanks to past research.

**MANUFACTURE**
Private companies and the U.S. government are investing in manufacturing. FDA is inspecting facilities earlier (while clinical trials are ongoing), which allows product to be manufactured for rapid distribution upon authorization/approval instead of during FDA review, in normal circumstances.

**CLINICAL TRIALS**
Clinical trials were carefully designed to test for safety, dosage, and effectiveness in phases that partially overlapped instead of running consecutively. Because COVID-19 is so widespread, finding people to participate in the clinical trials and assessing the vaccines' performance have been faster than normal.

**LICENSE/AUTHORIZATION**
An Emergency Use Authorization can be requested by vaccine developers for FDA to review preliminary data from clinical trials to determine if the benefit outweighs the risks for use in a public health emergency. The vaccine data must show safety and efficacy to earn an emergency use authorization.

**DISTRIBUTE**
Substantial U.S. government resources are being used to coordinate distribution to the public.